Calcium Hydroxyapatite (MCHC).

Active vitamin D raises the intestinal transporters that carry calcium and phosphate across the gut wall, the two minerals hydroxyapatite delivers. Vitamin D status sets how much of the dose is taken up.

Bone mineral is hydroxyapatite bound to K2-carboxylated osteocalcin. K2 is what directs the mineral this ingredient supplies into bone matrix.

Magnesium activates vitamin D and supports normal parathyroid signalling, and it is also substituted into the hydroxyapatite lattice itself. Both roles put it on the same pathway.

Bone is hydroxyapatite crystallised on a type I collagen scaffold, so collagen peptides and this mineral supply the two halves of the same tissue. Microcrystalline hydroxyapatite sources already carry some native collagen.

Ascorbate is the cofactor for prolyl and lysyl hydroxylase, the enzymes that crosslink the collagen scaffold hydroxyapatite deposits onto. Matrix quality decides where mineral can attach.

Boron influences calcium and magnesium handling in bone metabolism and lowers urinary calcium loss. It is a long-standing companion in bone mineral formulas.

Silicon is involved in collagen crosslinking, the protein scaffold that hydroxyapatite mineral binds to. Matrix and mineral are complementary rather than overlapping.

Manganese is the cofactor for the glycosyltransferases that build the glycosaminoglycan ground substance of bone and cartilage, the material mineral crystals sit in.

Strontium substitutes for calcium in both intestinal transport and the hydroxyapatite lattice, so simultaneous dosing lowers uptake of both. Standard practice separates the two.

Calcium lowers non-heme iron uptake at the enterocyte, and the phosphate in hydroxyapatite binds iron in the lumen as well. Iron belongs in a separate dose.

Supplemental calcium reduces zinc absorption from the same meal, and phosphate can bind zinc in the lumen too. Both parts of this salt work against the same zinc dose.

Calcium taken in the same dose as non-heme iron reduces iron uptake, an interaction documented across calcium salts. Chelated iron forms are somewhat less affected than simple salts but not exempt. Separating a calcium dose from an iron dose by two hours or more is the usual practical answer.

Hydroxyapatite is a poorly soluble crystalline calcium phosphate that has to be dissolved by gastric acid before the calcium becomes available for uptake. People with low stomach acid absorb acid-dependent calcium salts less well, and the standard advice is to take them with food, which itself triggers acid secretion. A supplemental acid source works on the same principle.

Fermentable oligosaccharides are broken down in the colon to short-chain fatty acids, which lower luminal pH and keep calcium in a soluble ionised form available for paracellular uptake in the large bowel. Studies in adolescents have measured higher fractional calcium absorption on inulin-type fibres. The size of the effect depends on the fibre dose and on how much calcium reaches the colon unabsorbed.

Short-chain fructooligosaccharides ferment faster and higher in the colon than long-chain inulin, producing the same acidification that favours calcium solubility. Mixtures of the two have been used specifically because they ferment along different stretches of the bowel. Fermentable fibre at higher doses brings gas and bloating for some people.

Galactooligosaccharides are fermented to short-chain fatty acids that acidify the colonic lumen and support calcium solubility there. This route matters most for the portion of a calcium dose that escapes small intestinal uptake, which grows as the dose grows. It does not replace vitamin D dependent absorption higher up.

Phytate from whole grains, legumes and seeds binds calcium into insoluble complexes in the gut, lowering how much is absorbed. Phytase cleaves phosphate groups from the phytate ring and releases the bound mineral. This matters most on plant-heavy diets taken alongside a mineral dose.

Caffeine produces a modest, measurable rise in urinary calcium loss in the hours after intake. At ordinary intakes with adequate calcium the effect is small and easily offset; it becomes relevant when calcium intake is already low. This is about calcium leaving in urine, not about how much is absorbed.

Sodium and calcium are reabsorbed together in the renal tubule, so a high sodium intake drags more calcium into the urine. Every additional gram or so of sodium raises urinary calcium loss measurably. The practical implication is that sodium intake is part of the calcium balance picture, not just the dose taken.

Potassium given as bicarbonate or citrate lowers urinary calcium loss by reducing the net acid load the kidney has to buffer. Potassium chloride does not do this, because the effect belongs to the alkaline anion rather than to potassium itself. The distinction is often collapsed in product copy and it should not be.

An alkali load lowers urinary calcium excretion by reducing the acid the kidney must buffer, an effect shown with bicarbonate salts. The sodium that comes with sodium bicarbonate works in the opposite direction on the same measure, so the net result depends on the balance of the two. Potassium bicarbonate does not carry that offsetting sodium.

Osteocalcin, the main non-collagen protein in bone matrix, must have its glutamate residues carboxylated by a vitamin K dependent enzyme before it can bind calcium. Phylloquinone from green vegetables is the dominant dietary form and feeds that reaction. It works on where the calcium ends up, not on how much is absorbed.

Hydroxyapatite already supplies calcium and phosphate together in roughly the ratio found in bone, unlike carbonate or citrate salts which supply calcium alone. Adding further phosphorus on top of a diet already rich in it, from cola and processed food, shifts the calcium to phosphorus ratio rather than improving it. This is the specific reason a phosphate-containing calcium source and a phosphorus supplement are an odd pairing.

Higher protein intake raises urinary calcium output but also raises intestinal calcium absorption, and when calcium intake is adequate the net balance is favourable. When calcium intake is low, the loss side is the one that shows. This is why protein was once described as a calcium drain and is now regarded as neutral to helpful at adequate calcium intakes.

Cohort studies have linked very high intakes of preformed vitamin A, retinol rather than beta-carotene, with reduced bone density measurements. That is an association drawn from observational data and does not establish cause. Beta-carotene has not shown the same signal, because its conversion to retinol is regulated.

Lactoferrin acts on bone-forming cells in culture and in animal models, which is why it appears in bone formulas next to a calcium source. Human evidence at supplement doses is thin. Regard the calcium and vitamin D components as the characterised part of such a formula.

Strains that ferment fibre to short-chain fatty acids lower colonic pH, the same route by which prebiotic fibres support calcium solubility in the large bowel. Direct measurement of calcium absorption with a probiotic alone is limited. The fermentable substrate is the part with the stronger human data.